VARUBI (rolapitant)

VARUBI (rolapitant)

INJECTABLE-OFFICE ADMINISTRATION; ORAL-SELF ADMINISTRATION

Indications for Prior Authorization:

• Indicated for combination use with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy

Patients must meet the following criteria for the indication(s) above:

• Patient is 18 years of age or older, AND
• Patient is receiving Varubi for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, AND
• Patient is not taking CYP2D6 substrates with a narrow therapeutic index (e.g. thioridazine and pimozide)
• Ensure patient is not hypersensitive to any component of the product (e.g. soybean oil) and check for cross reactions to other allergens (e.g. allergies to legumes or other related allergens)

Dosing:

• 180mg orally as a single dose administered within 2 hours prior to initiation of chemotherapy, OR
• Infuse 166.5 mg over 30 minutes within 2 hours prior to initiation of chemotherapy